Study on Combining Radiation Therapy with Durvalumab for Pancreatic Cancer

Inclusion Criteria

• Diagnosed with pancreatic cancer that is locally advanced or borderline resectable, as confirmed by medical tests.
• Previously treated with FOLFIRINOX chemotherapy for 3-6 months, with stable disease shown in follow-up imaging.
• A break of no more than 6 weeks between finishing chemotherapy and starting the study treatment.
• Aged 18 years or older.
• Weigh more than 30 kg (about 66 pounds).
• In good general health with an ECOG performance status of 0 to 2.
• Normal organ and bone marrow function, as shown by specific blood test results.
• Women of childbearing potential must have a negative pregnancy test before starting treatment and agree to use effective contraception.
• Men must agree to use effective contraception if sexually active with a woman of childbearing potential.
• Able to understand and willing to sign a consent form.
• Willing to follow the study protocol, including treatment and follow-up visits.

Exclusion Criteria

• History of another cancer, unless treated successfully and inactive for at least 2 years.
• Previously received other anti-cancer treatments not specified in the study.
• Women who are breastfeeding.
• Significant unresolved side effects from previous cancer treatments, except for hair loss or skin changes.
• Currently receiving other investigational treatments for cancer.
• Previous treatment with PD1 or PD-L1 inhibitors, including durvalumab.
• Known spread of cancer to other parts of the body.
• Recent major surgery within 30 days before starting the study treatment.
• Allergic reactions to similar drugs as durvalumab.
• Uncontrolled illnesses, such as infections or heart problems, that could interfere with the study.
• Receiving radiation treatment outside of the study centers.
• Active autoimmune or inflammatory disorders, except for certain stable conditions.
• Use of immunosuppressive medications within 28 days before starting the study, except for chemotherapy.
• History of organ transplant requiring immunosuppressive drugs.
• Active infections, including hepatitis B, hepatitis C, or HIV.
• Recent live vaccinations within 30 days before starting durvalumab.
• Any condition that could interfere with the study or affect patient safety.